How good would that be.
And then on a completely different indication, a gene therapy treatment that has some safety concerns, may be able to lower their dose amount, when combined with ATL1102. helping safety. helping efficacy.
And then there are the other indications, and that approval trial for DMD in non ambulant boys.
Exciting 18 months to come.
How good would that be. And then on a completely different...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
